Our understanding of glioblastoma multiforme (GBM), the most common form of primary brain cancer, has been significantly advanced by recent efforts to characterize the cancer genome using unbiased high-throughput sequencing analyses. While these studies have documented hundreds of mutations, gene copy alterations, and chromosomal abnormalities, only a subset of these alterations are likely to impact tumor initiation or maintenance. Furthermore, genes that are not altered at the genomic level may play essential roles in tumor initiation and maintenance. Identification of these genes is critical for therapeutic development and investigative methodologies that afford insight into biological function. This requirement has largely been fulfilled with the emergence of RNA interference (RNAi) and high-throughput screening technology. In this article, the authors discuss the application of genome-wide, highthroughput RNAi-based genetic screening as a powerful tool for the rapid and cost-effective identification of genes essential for cancer proliferation and survival. They describe how these technologies have been used to identify genes that are themselves selectively lethal to cancer cells, or synthetically lethal with other oncogenic mutations. The article is intended to provide a platform for how RNAi libraries might contribute to uncovering glioma cell vulnerabilities and provide information that is highly complementary to the structural characterization of the glioblastoma genome. The authors emphasize that unbiased, systems-level structural and functional genetic approaches are complementary efforts that should facilitate the identification of genes involved in the pathogenesis of GBM and permit the identification of novel drug targets. (DOI: 10.3171/2009.10.FOCUS09212) of the molecular networks governing cancer pathogenesis can be translated into substantial clinical benefits.
However, human cancers harbor hundreds of genetic alterations, and only a subset of these alterations likely drive tumor initiation and maintenance, making it difficult to identify which mutations are the critical drivers of cell transformation, and how multiple mutations within single cells interact to promote tumorigenesis. Furthermore, genes not altered at the genomic level play essential roles in tumor development, in so-called "nononcogene addiction." 29 For instance, cancer cells exhibit increased dependence on the heat shock response, although genes required for this response are not oncogenic.
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Given the limitations inherent within the genomic approach, a systematic functional assessment of the contribution of specific genes to cancer phenotypes is an alternative but complementary approach to structural characterizations of the cancer genome. The recent development of genome-wide human RNAi libraries has enabled systematic genetic studies in normal and human breast and colon tumor cells using arrayed and pooled screens. [3] [4] [5] 12, 19, 24, 27, 33 It seems likely that systematic RNAi screens aimed at generating either cancer lethal signatures using a large panel of cancer and normal human cell lines, or synthetic lethal signatures against specific oncogenes or tumor suppressors or cells, should reveal the key glioma cell vulnerabilities that could serve as the basis for the rational design of novel therapeutics.
Mutational Analysis of the GBM Genome
A traditional approach used to discover novel drug targets is to identify genetic lesions in cancer cells and exploit this knowledge for therapeutics. Such an approach is currently used by the Cancer Genome Atlas and other similar efforts that aim to characterize-in a large number of cancer types-genomic alterations, including copynumber variation, transcriptional profiles, epigenetic modifications, and DNA sequence alterations. This approach has the potential to identify common alterations in oncogenes and tumor suppressors for further functional analysis and to uncover oncogene addiction pathways that can be targeted. 7, 21 For example, Yan et al., 36 by sequencing 20,661 protein-coding genes, determining the presence of amplifications and deletions using high-density oligonucleotide arrays, and performing gene expression analyses using next-generation sequencing technologies in 22 human GBM samples, found alterations in a variety of previously known and unknown GBM-associated genes. Most notably, novel mutations in the active site of isocitrate dehydrogenase 1 (IDH1), were demonstrated in 12% of patients with GBM; most of these mutations occurred in a large fraction of young patients and in most patients with secondary GBMs and were associated with an increase in overall survival.
In the Cancer Genome Atlas study, besides recapitulating the mutational events in GBM that have been known for decades on a large scale, the authors found that some genetic lesions-such as TP53 mutation, NF1 deletion or mutation, and ERBB2 amplification-were more common than previously reported. 7 Together, these systemslevel studies identified the major genetic events in human GBMs, 7, 21 including: 1) dysregulation of growth factor signaling via amplification and mutational activation of receptor tyrosine kinase (RTK) genes; 2) activation of the phosphatidylinositol-3-OH kinase (PI(3)K) pathway; and 3) inactivation of the p53 and retinoblastoma (Rb) tumor suppressor pathways. Recent genome-wide profiling studies have also demonstrated the remarkable genomic heterogeneity among GBMs, along with the existence of different molecular subclasses of GBMs that may allow for treatment stratification.
13,22 However, with rare exceptions, such as IDH1, few of the discoveries from these structural studies are anticipated to generate immediately actionable drug targets; for common but currently undruggable oncogenes such as RAS, and tumor suppressors, such as PTEN and TP53, the Cancer Genome Atlas will likely provide little translational insight.
Limitations of Structural Analyses of Cancer Genomes for Drug Discovery
Although informative, structural genetic approaches have limitations with respect to target discovery. First, current sequencing capacity is largely limited to coding regions, though whole-genome sequencing will become feasible with the development of cheaper and more highly parallel sequencing methods. Second, targeting oncogene addiction alone is unlikely to be a solution because: 1) many known oncogenes are challenging therapeutic targets (for example, efforts to develop drugs that inhibit oncogenic RAS proteins have been largely unsuccessful, despite the fact that RAS is mutated in nearly 30% of human tumors and is essential for their viability); 2) although recent sequencing/mapping efforts have revealed hundreds of potential oncogenic mutations and gene copy alternations, without functional characterization it is unknown which of these mutations make good drug targets; and 3) because tumors rapidly develop resistance to targeted therapy with single agents, multiple agents with different mechanisms of action are necessary to suppress drug resistance.
In addition to oncogene addiction, the stress phenotype of cancer cells makes them more dependent on the function of certain essential genes that are not themselves oncogenes or otherwise mutated; however, many if not all of these proteins can be rate-limiting to their pathways. Elledge and colleagues coined this phenomenon of cancer cells the "non-oncogene addiction." 29 The cancer cells' increased dependence on the heat shock response and their metabolic adaptation for aerobic glycolysis are 2 examples of non-oncogene addiction that have received therapeutic attention. 6, 35 Because genes involved in nononcogene addiction do not themselves harbor genetic alterations, they will be missed by DNA sequencing efforts alone. Therefore, the identification of non-oncogene addiction genes requires functional approaches.
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Functional Genomics: An Alternative Method for Exploring Cancer Cell Vulnerabilities
A second approach takes that of functional systems biology to identify cancer cell vulnerabilities. 19, 24, 27 Advances in RNAi technology in human cancer cell lines have made it possible to systematically interrogate genes for potential roles in tumorigenesis. By silencing or decreasing the expression of specific gene products in cancer-specific assays, these loss-of-function screens can provide insight into their biological function.
A functional genetic approach using genome-wide RNAi offers several advantages in target discovery over structural genomics: 1) RNAi-mediated protein knockdown results in either partial or complete loss of function, oftentimes mimicking the effect of a potential pharmacological inhibitor; 2) RNAi can be applied in an unbiased manner to any annotated gene in the human genome based on sequence information alone without a priori knowledge of the gene's mutational status or biological function, thereby helping uncover novel cancer genes; 3) RNAi can be readily applied in mammalian model systems (including the many different mouse models of cancer), thus providing an opportunity for rapid target validation in vivo without first developing a drug that inhibits the gene product of interest; 4) RNAi screening has the ability to identify genes not mutated in cancers and exhibit features of non-oncogene addiction.
It is possible to induce RNAi-mediated gene knockdown transiently by the introduction of chemically synthesized small interfering RNAs (siRNAs), or stably by plasmids or viruses expressing RNA short hairpins (shRNAs), which are subsequently processed into siRNAs by the protein Dicer. Via either mechanism, the resulting siRNA directs degradation or translational suppression in a sequence-specific manner of the mRNA of the gene of interest by becoming incorporated into the RNA-induced silencing complex (RISC), resulting in decreased protein expression (Fig. 1) . While chemically synthesized oligonucleotide siRNAs are effective in inducing gene suppression, such reagents are expensive and can only be used for transient loss-of-function experiments. This is limiting for many assays specific for cancer-related phenotypes, such as anchorage-independent colony formation or tumor xenografts, where long-term gene suppression is required. Vector-based RNAi systems have circumvented this problem by providing stable expression of the RNAi in mammalian cells through incorporation of the construct into the DNA of the host cell's genome. These vector-based systems also have the added benefit of being a renewable resource because of their propagation in Escherichia coli. Moreover, vector-based systems can be used to create retroviruses that harbor the RNAi construct, thereby expanding the type of cells into which such constructs can be introduced. 20, 23, 26 Both siRNA and shRNA libraries have been used successfully in transfection-based arrayed screens investigating phenotypes that develop shortly after gene suppression, such as apoptosis, cell signaling events, or cell cycle distribution. 1, 11, 34 The use of RNAi provides a straightforward, func- In the latter case, the shRNA sequences integrate into the host genome and are expressed via Pol II- or Pol III-mediated transcription. The shRNAs are then processed by Dicer into double-stranded siRNA. Via either mechanism, the resulting siRNA becomes incorporated into a RISC, which directs target mRNA degradation or translational suppression in a sequence-specific manner, thus resulting in decreased protein expression.
tional approach to identify new cancer drug targets by identifying genes whose knockdown is lethal to cancer cells but not normal cells. To gain statistical power, one must screen multiple cancer and normal cell lines. Because of the sheer scale of screening that is required, the standard siRNA transfection or shRNA transduction screen in a well-by-well format using multiwell plates is prohibitively expensive and time consuming. Currently, several laboratories are equipped to execute such highthroughput approaches to manipulate gene expression in mammalian cell lines. However, novel technologies are developing that will make it cheaper and easier to execute such large-scale screens. Barcoded shRNA libraries, together with pool-based screening platforms, circumvent these barriers to large-scale screening (Fig. 2) . Elledge and colleagues have pioneered the construction of shRNA libraries that target the human genome and have optimized delivery vectors that allow potent shRNA expression and efficient gene knockdown; these efforts have resulted in a barcoded, microRNA-based shRNA library targeting the entire human genome that can be expressed efficiently from either retroviral or lentiviral vectors in a variety of cell types for stable gene knockdown. 20, 26, 27 The current generation shRNA library consists of 87,283 shRNAs targeting 32,216 human genes, with an average of 3 distinct shRNA sequences per gene.
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There are 3 unique advantages of the Elledge-Hannon shRNA library: 1) The shRNA is embedded in the backbone of a naturally occurring microRNA, mir30, enabling efficient expression and processing of the shRNA for incorporation into the RISC (Fig. 3) ; 2) the shRNA of interest is cloned into a modified retroviral vector permitting sufficient expression so that single proviral integration is sufficient for gene knockdown-an essential characteristic for a pool-based, ultra high-throughput screening platform; and 3) each shRNA is tagged with a unique 60-nucleotide barcode sequence that can be used to track its abundance in a pool by microarray hybridization (Fig. 3) . 20, 26, 27 Elledge and colleagues have also developed an ultra high-throughput platform (see below) to screen complex pools of shRNAs using barcodes coupled with microarray deconvolution. Barcodes are critical for pool-based dropout screens that are designed to identify cell-lethal or drug-sensitive shRNAs 19 and provide independent means to track the abundance of shRNAs in a complex pool. Hairpins depleted over time can be identified through the competitive hybridization of barcodes derived from the shRNA population before and after selection to microarrays. 21, 27, 28 This technology can handle more than 10,000 shRNAs per pool and involves low costs.
27,34
Cancer Lethal Signatures
The central goal for developing pool-based shRNA screening platforms is to attain the means to rapidly perform dropout screens for the systematic identification of genes required for cancer cell proliferation and survival that could represent new drug targets. A proof-of-principle screen using the Elledge-Hannon shRNA library in human colon and breast cancer cells has recently been published. 24 In their study, Schlabach et al. 24 used a highly complex pool of 8203 distinct shRNAs targeting 2924 genes consisting of annotated kinases, phosphatases, ubiquitination pathway and cancer-related genes-all central regulators of signaling pathways that should provide a rich source of phenotypic perturbation-to interrogate multiple human colon cancer and breast cancer cell lines, and normal human epithelial cell lines. Two types of cancers with distinct origins were compared with identified common and cancer-specific growth regulatory pathways. Cells were infected with an average representation of 1000 per shRNA and an MOI of 1-2. Initial reference samples were collected 2-3 days postinfection; the remaining cells were puromycin-selected, propagated for several weeks, and collected again as the end samples. Polymerase chain reaction was used to recover the halfhairpin (HH) barcodes from genomic DNA, labeled with Cy5 and Cy3 dyes, respectively, and hybridized to an HH barcode microarray. For each probe, the Cy3/Cy5 signal ratio reports the change in relative abundance of a particular shRNA between the beginning and the end of the experiment. An shRNA that causes growth inhibition or cell death will drop out from the pool over time and show a log 2 Cy5/Cy3 ratio of < 0. Conversely, a shRNA that enhances cell proliferation will enrich in the pool over time and show a log 2 Cy5/Cy3 ratio of > 0. Lastly, an shRNA that has little effect on cell growth will show a log 2 Cy5/ Cy3 ratio of ~ 0. Whereas the majority of shRNAs show little changes in their abundance over time (log 2 ratio between -1 and 1), a small fraction of shRNAs dropped out over time (log 2 ratio < −1), reflecting differences between cancer and normal cells. Interestingly, the 2 colon cancer cell lines were more similar to each other than to the breast cancer line, likely reflecting tissue-specific differences and mechanisms of tumorigenesis.
As expected, the screen recovered multiple components of core cellular pathways essential for survival; for example, shRNAs against multiple subunits of the anaphase promoting complex (APC/C) and the eukaryotic translation initiation factor 3 (eIF3) complex were lethal in all cell types. In addition to the common set of shRNAs that impair viability in all cell lines, a number of genes selectively required for proliferation of individual cell lines were identified, including PPP1R12A-a regulatory subunit of protein phosphatase 1; PPP1R12A was selectively required for breast cancer cell viability, but not colon cancer cell viability. Conversely, colon cancer cell lines were more sensitive to knockdown of PRPS2, a gene involved in nucleoside metabolism. Importantly, comparison of the lethal signatures between breast cancer cell lines and nontransformed human mammary epithelial cell lines identified a number of genes-including the cell cycle regulator kinase gene BUB1-whose knockdown caused greater toxicity to breast cancer cells than normal mammary epithelial cells, suggesting BUB1 could be further explored as a potential drug target for the treatment of breast cancer.
This study proved the feasibility of ultra highthroughput dropout screens with highly complex pools of shRNAs with barcode microarray deconvolution to identify lethal shRNAs for multiple cancerous and normal epithelial cell lines. These studies resulted in the discovery of genes that are essential for general cell viability and are selectively required for cancer cell viability. Others have described the development and application of genome-scale high-throughput methods using lentiviral RNAi libraries to systematically assess cancer gene function and to integrate structural and functional approaches in the study of cancer. 17 
Synthetic Lethal Signatures
"Synthetic lethality" occurs when alteration of a gene results in cell death only in the presence of another genetic mutation. Cancer cells, due to oncogenic mutations, develop secondary dependencies on genes that are themselves not oncogenes. This fact is exploited in synthetic lethal genetic screens, where perturbation of genes within the same pathway, a parallel pathway, a distant pathway, or in genes with other essential cellular functions, result in oncogene-specific synthetic lethal interactions, thereby defining novel therapeutic targets.
9,10 Synthetic lethal interactions were first described in model organisms like yeast and worms, 2, 16 but recent studies have demonstrated the concept of synthetic lethality is relevant for mammalian cells. 28, 30 The use of RNAi is also relevant for identifying genetic interdependencies in human cancer; functional genetic screens have identified genes whose knockdown sensitizes cancer cell lines 31, 34 or untransformed cells with ectopic oncogene expression to the effects of specific environmental conditions, like a drug.
Recently, in synthetic lethality screens using shRNAs in human cancer cells expressing mutant K-RAS, Gilliland and colleagues and Elledge and colleagues identified 2 different kinases-STK33 (serine/threonine kinase 33) and PLK1 (polo-like kinase 1)-respectively, as potential novel drug targets for RAS-driven cancers. 18, 25 In a panel of 8 human cancer cell lines (4 K-RAS wild-type and 4 K-RAS mutant), using a well-by-well approach in which the biological effects of each hairpin are scored individually, Gilliland and colleagues screened 5000 shRNAs targeting 1000 genes. Annotation of the hits that scored specifically in the 4 K-RAS mutant lines yielded a small list of genes, which included STK33 at the top of the list. This gene was validated in separate in vitro assays, and in vivo in tumor xenograft models. This large-scale, wellby-well screening approach requires an expensive highthroughput platform that, while powerful, would likely be difficult for most other academic labs to recapitulate. Scaling such technology for genome-wide screens would also be challenging.
Elledge and colleagues use a pooled screening approach with an isogenic cell line pair. In their screen, a library of 75,000 shRNAs targeting 30,000 mRNA transcripts from 12,000 genes was introduced into a K-RAS mutant cancer cell line as well as an isogenic wild-type K-RAS control. 18 As detected by barcode arrays, shRNAs targeting 400 genes were selectively depleted in K-RAS mutant cells after multiple population doublings. These genes were deemed candidate RAS synthetic lethal genes. A subset of these were validated in a repeat screen in another K-RAS mutant isogenic cell line pair, resulting in a list of 77 validated RAS synthetic lethal genes. Due to the larger scale of the screening approach, no single gene was classified as a top hit; however, computational analysis revealed increased dependence of K-RAS mutant cells on multiple genes involved in mitotic machinery (including the kinase gene PLK1) and the proteasome. Consistent with these results, K-RAS mutant cells were preferentially killed by drugs like paclitaxel (which target mitotic spindle function), a preclinical PLK1 inhibitor, and bortezomib (a proteasome inhibitor). These data also bolstered the notion that cancer cells must adapt to avoid stressinduced death associated with their actively proliferating state. Standard chemical approaches should be able to identify inhibitors of these kinases. Ultimately, validation of the synthetic lethal screening strategies outlined will be achieved if patients with K-RAS mutant tumors benefit from treatment with STK33 or PLK1 inhibitors.
Future Directions
Within a short time of its discovery, RNAi has emerged as the preferred means for studying gene function. Marriage of RNAi to high-throughput screening technologies has revolutionized biological and biomedical investigations. Applications of genome-wide RNAi screens to GBM will undoubtedly unveil genes critical for tumor initiation and vulnerabilities inherent within the cancer cells. The hybridization of this information with the genomic landscape as characterized by the sequencing efforts will yield novel insights into glioblastoma pathogenesis and shape strategies for therapeutic development.
